TWiV explores single dose administration and timing of second dose of AZD1222 COVID-19 vaccine, safety and efficacy of Sputnik V, and control of coronavirus recombination by a viral proofreading exonuclease.
Theodora and Paul return to TWiV to explain how they quickly pivoted their retrovirus laboratories towards SARS-CoV-2, their work on the antibody response to infection and its durability, and the emergence of variants with increased resistance to neutralization.
In COVID-19 clinical update #48, Daniel Griffin reviews effect of spike amino acid changes on neutralization with monoclonal antibodies, Sputnik V safety and efficacy results, increased reactogenicity after a single vaccine dose in seropositive individuals, single dose vaccination in seropositive health care workers, and results of three clinical trials on the use of anticoagulants.
TWiV explains why hydroxychloroquine failed in humans despite showing antiviral effects in cells, and reviews the published data on the Pfizer/BioNTech mRNA vaccine.
Jason McLellan joins TWiV to reveal all we know about the SARS-CoV-2 spike protein, followed by Novavax and J&S phase 3 results and a discussion of variants of concern: neutralization by vaccine-induced antibodies, transmission, and virulence.
In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease.
The TWiVers review Biden’s national strategy for COVID-19 responses and pandemic preparedness, and an evaluation of the BinaxNOW rapid antigen test for SARS-CoV-2 infection.
In COVID-19 clinical update #46, Daniel Griffin discusses the BinaxNow rapid antigen test, efficacy of Bamlanivimab in nursing homes, associations of serum vitamin D concentrations with in-hospital mortality and need for invasive mechanical ventilation, trials of IL-6 receptor antagonists, effects of anticoagulants on in-hospital mortality, and symptom persistence in outpatients.
In this episode, President Biden elevates his science advisor to his Cabinet, a review of the current flu season, the scientific goals of the WHO-convened Global Study of the Origins of SARS-CoV-2, and answers to listener questions.
The TWiVy team deconstructs CoronaVac, the inactivated SARS-CoV-2 vaccine produced by Sinovac Biotech, and production of multivalent camelid nanobodies that block infection with the virus and suppress selection of neturalization-resistant variants.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.